Multi-agent Chemotherapy (e.g., Hyper-CVAD regimen)
Treatment for Acute Lymphoid Leukemia
Typical Dosage: Highly protocol-specific, involves multiple drugs (e.g., Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine)
Effectiveness
75%
Safety Score
25%
Clinical Trials
1
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Highly protocol-specific, involves multiple drugs (e.g., Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine)
Time to Effect
4-8 weeks (for remission)
Treatment Duration
2-3 years (induction, consolidation, maintenance)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$75,000
Side Effect Mgmt:$100,000
Total Annual:$225,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$264,706
Cost per Remission
$300,000
Multi-agent Chemotherapy (e.g., Hyper-CVAD regimen) Outcomes
for Acute Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+85%
Remission Rate
+75%
Common Side Effects
Myelosuppression (Neutropenia, Anemia, Thrombocytopenia)
+90%
Nausea and vomiting
+70%
Fatigue
+80%
Mucositis
+50%
Infection
+60%
Alopecia
+80%
Active Clinical Trials
1 active trial recruiting for Multi-agent Chemotherapy (e.g., Hyper-CVAD regimen) in Acute Lymphoid Leukemia
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
NCT07059156RECRUITINGPHASE2, PHASE3
50 participants
INTERVENTIONAL
Taiyuan, China
Started: Jun 1, 2025